“Federal policy must reflect evidence and science, not dispelled myths and tired stereotypes.”
By Sasha Kalcheff-Korn, National Compassionate Care Council
Recent federal action initiating a review of cannabis scheduling and signaling interest in expanding cannabinoid research reflects a growing willingness to examine how federal policy aligns with emerging evidence and real-world patient experience—but it also highlights a significant research gap that must still be addressed. If approached thoughtfully, this moment represents a rare opportunity to bring scientific rigor, clearer regulatory standards and responsible oversight to a space that has operated within a fragmented, state-by-state system for decades.
The new National Compassionate Care Council, announced this week, was formed to help meet that moment.
We represent the healthcare-aligned sector of the cannabis industry—from physicians to patients to responsible manufacturers—united around a single mission: turning executive momentum into durable policy that actually reaches people.
This is not about advancing an industry for its own sake. It is about ensuring that when patients and healthcare providers discuss cannabinoid therapy, they can do so within a clear, evidence-informed federal framework.
Opportunities like this do not move forward automatically. Opponents are already lining up to impede this progress.
Rep. Andy Harris (R-MD) declared openly that
Read full article on Marijuana Moment
